EVOTEC SE INH O.N.
Commented by Fabian Lorenz on March 20th, 2026 | 09:00 CET
Which stock to buy now? Evotec, Nel, and Lahontan Gold in focus
What is driving Nel's sudden rebound? Within just a few days, the former hydrogen hopeful has surged more than 20% in value, breaking out of its short-term downtrend. Yet analysts do not see a trend reversal. Instead, they point to a risk in the order backlog. In contrast, the gold explorer Lahontan Gold currently offers an interesting entry opportunity following a sharp correction. The company aims to expand the resource estimate of its flagship Nevada project beyond 2 million ounces. If successful, the stock could be materially undervalued. Evotec, on the other hand, continues to struggle with investor sentiment. Even a recent milestone payment failed to provide positive momentum, with the stock declining further yesterday.
Read
Commented by André Will-Laudien on March 13th, 2026 | 08:35 CET
Bull market or bear market? Not all that glitters is gold! Evotec, TeamViewer, and Lahontan Gold under review
With volatility at current levels, investors are looking for stable stocks. That is not easy, because on days when oil prices start the morning with a USD 35 premium, stocks are sometimes sold off in a panic. This is a paradise for traders, an opportunity for long-term investors, and a costly mistake for the nervous. This is how modern stock markets operate: AI-driven trading algorithms anticipate possible scenarios based on volatility patterns and reshape order books within milliseconds. For private investors, the key is to keep their nerve and separate the wheat from the chaff. We take a closer look at Evotec, TeamViewer, and Lahontan Gold. Because where there is light, there is also shadow.
Read
Commented by Fabian Lorenz on March 12th, 2026 | 07:25 CET
Breaking News! Takeover speculation? BioNTech, Evotec, Vidac Pharma
First, the positive news: Vidac Pharma's drug candidate VDA-1102 was recently used in a compassionate treatment case in connection with a girl's third brain surgery. Following the treatment, the patient's condition improved significantly. In addition, the Vidac platform is now being tested beyond oncology. 2026 could mark a potential breakthrough year for the company and its stock. It was a different story this week for BioNTech, whose shares suffered a sharp setback. The rather mixed results for 2025 and the cautious outlook for the current year likely played only a limited role. More troubling for shareholders is likely the impending departure of the founding couple. This raises the question: Could BioNTech become a takeover target? There were also long faces at Evotec this week. The company's restructuring program has failed to convince the market, and the stock has slipped below an important technical support level.
Read
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Armin Schulz on February 3rd, 2026 | 07:05 CET
Zinc boom, turnaround, and biotech growth: How to profit with Pasinex Resources, Puma, and Evotec
In volatile markets, investors are looking for exceptional opportunities. Three companies stand out in this regard. A commodities company with exceptional zinc projects, a sporting goods manufacturer undergoing radical transformation, and a biotech pioneer with a unique platform model. The combination of momentum, strategic turnaround, and long-term growth promises attractive return opportunities. We analyse the promising prospects of Pasinex Resources, Puma, and Evotec.
Read
Commented by Fabian Lorenz on January 29th, 2026 | 07:00 CET
Puma takeover is becoming more concrete! Should investors buy Evotec and Silver Viper shares next?
Takeover speculation has been swirling around Puma for some time. Now it has become more tangible: Anta has secured a 29% stake in the German sporting goods group, paying EUR 35 per share. However, the euphoria on the stock market is limited. Are there better opportunities for investors to profit from takeover speculation? One candidate in the hot silver market is Silver Viper. The Company is pushing ahead with exciting projects in Mexico. Its recent capital increase met with strong demand, and a financially powerful potential buyer already has a foot in the door. And what about Evotec? The perennial takeover candidate is still not gaining momentum. That said, the biotech company is benefiting from the sale of one of its own holdings, which is expected to bring in around USD 160 million.
Read
Commented by Armin Schulz on January 21st, 2026 | 08:25 CET
Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Three stocks on the verge of a decisive turning point?
Germany's economy is at a crossroads. Its old strengths are crumbling, but this is precisely what opens up opportunities for companies that are strategically realigning themselves. The key to success is not simple adaptation, but a fundamental turnaround. Three decisive paths are emerging: disruptive innovation in the biotech industry, energy production and decarbonization, and the development of sovereign digital networks. Today, we take a closer look at three companies and analyze which stocks are on the verge of a turnaround: Evotec, A.H.T. Syngas Technology, and Deutsche Telekom.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Carsten Mainitz on December 30th, 2025 | 11:15 CET
Stock Picking Alert! Power Metallic Mines – Set to Double? Puma and Evotec as Promising Turnarounds?
The 2025 stock market year has produced many winners, but also some losers. Bullish commodity markets and project progress led to a jump in the share price of Canadian commodity company Power Metallic Mines at the beginning of the year. In December, the share price corrected, but the upward trend quickly resumed, buoyed by good drilling results. The Canadian company holds one of the largest polymetallic deposits in North America, which has attracted many well-known investors this year. It is also worth taking a look at turnaround bets with takeover potential, such as Evotec and Puma.
Read